Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 19/20 | 0.43 |
| ▸ | CBLC | Q9ULV8 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CBL | P22681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527977 | 1.00 | CBLB (0.43) | CBLBCBLCOPRM1OPRK1CBL | |
| SCHEMBL31314829 | 1.00 | CBLB (0.43) | CBLBCBLCOPRM1OPRK1CBL | |
| SCHEMBL29841425 | 1.00 | CBLB (0.43) | CBLBCBLCOPRM1OPRK1CBL | |
| SCHEMBL31314827 | 1.00 | CBLB (0.43) | CBLBCBLCOPRM1OPRK1CBL | |
| SCHEMBL22527975 | 1.00 | CBLB (0.43) | CBLBCBLCOPRM1OPRK1CBL | |
| SCHEMBL21200283 | 0.89 | CBLB (0.47) | CBLBCBLC | |
| SCHEMBL21200193 | 0.89 | CBLB (0.47) | CBLBCBLC | |
| SCHEMBL29867231 | 0.89 | CBLB (0.47) | CBLBCBLC | |
| SCHEMBL21200463 | 0.89 | CBLB (0.47) | CBLBCBLC | |
| SCHEMBL29841648 | 0.89 | CBLB (0.47) | CBLBCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11464802-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3953346-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | Nurix Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210508-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3461/4885 |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3461/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3461/4885 |
| US-11464802-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3461/4885 |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3461/4885 |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885OPRM1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.